Skip to content

The Diagnostic and Prognostic Value of Speckle Tracking Imaging in Septic Cardiomyopathy

The Diagnostic and Prognostic Value of Speckle Tracking Imaging in Septic Cardiomyopathy: a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05624619
Enrollment
150
Registered
2022-11-22
Start date
2022-12-18
Completion date
2025-12-31
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies, Echocardiography, Sepsis

Brief summary

The aim of this study is to explore if STI technology, especially TMAD, plays an important role in evaluating left ventricular longitudinal systolic function and discriminating SICM in patients with sepsis. The investigators also intend to prove that TMAD may have predictive value in patients with sepsis, which is worthy of in-depth study to find strong evidence-based medical evidence for subsequent clinical practical applications.

Detailed description

In order to explore if STI technology, especially TMAD, plays an important role in evaluating left ventricular longitudinal systolic function and discriminating SICM in patients with sepsis, the investigators intend to explore that TMAD may have predictive value in patients with sepsis, which is worthy of in-depth study to find strong evidence-based medical evidence for subsequent clinical practical applications.

Interventions

None listed

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients who are diagnosed as sepsis according to sepsis 3.0 criteria

Exclusion criteria

* patients with history of organic heart disease; * patients with history of heart failure * holder of cardiac implanted device; * patients with history of atrial fibrillation; * refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
28-day mortality28 days28-day mortality of sepsis

Countries

China

Contacts

Primary ContactJieqiong Song
song.jieqiong@zs-hospital.sh.cn13917056745

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026